



































Since Hayflick’s discovery of the phenomenon of 
cellular (replicative) senescence [1], the contribution or 
even relevance of this phenomenon to organismal aging 
has been a subject for continuous debates [2-5]. 
Although the question still remains open, an increasing 
amount of evidence, especially from recent years, 
indicates that cellular senescence (CS) could have a role 
in aging and age-related diseases (ARDs), rather than 
being just a laboratory phenomenon [3, 6-11]. In fact, 
the current situation in the field could be defined as an 
attempt to understand to what extent and how is CS 
involved in aging and ARDs.  
 
Apart from an irreversible growth arrest (“Hayflick’s 
limit”  ― a finite number of cell divisions), the CS 
phenotype is characterized by cell hypertrophy, an 
increased   metabolic   activity  including  synthesis   of  
 
 


































macromolecules (RNA, protein, lipid) and organelles 
[12, 13], increased secretion of pro-inflammatory 
substances and resistance to apoptosis [7, 8, 11]. After 
being initially discovered in primary cultures of human 
fibroblasts, CS has also been found in other cell types 
such as keratinocytes, endothelial cells, lymphocytes, 
adrenocortical cells, vascular smooth muscle cells, 
chondrocytes, etc., both for in vitro and in vivo 
conditions [3, 11, 14, 15], and in cell cultures derived 
from many other organisms examined thus far (e.g., 
mice, monkeys, chickens, Galapagos tortoise, etc.) [16-
18]. Moreover, it appears that CS is not restricted only 
to dividing cells. At least some features of CS were also 
found in classical post-mitotic cells such as neurons, 
myocardiocytes and adipocytes (reviewed by Tchkonia 
et al. [19]). 
 
The complex nature of aging and aging-associated 

























and  aging‐associated  conditions  (oxidative  stress  and  chronic  inflammation)  are  growth‐promoting  pathways  and  the
pathways responsible for cell‐extracellular matrix interactions and stress response. Of note, the patterns of evolutionary
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20, 21]. Here we consider the potential molecular links 
between CS, longevity, ARDs, oxidative stress, and 
chronic inflammation from a systems biology perspec-
tive. Highlighting the common genes, interactions, 
regulatory molecules (miRNAs) and common pathways 
may help in understanding how CS interplays with and 
contributes to other aging-associated conditions.  
 
RESULTS AND DISCUSSION 
 
1. CS genes share common features with LAGs and 
ARD genes 
 
A comprehensive data mining of scientific literature 
brought about a list of 262 human genes identified as 
being associated with CS (see Suppl. Table 1). These 
genes possess diverse functions, with the majority 
falling into three categories: regulation of cell cycle and 
proliferation, biosynthesis and programmed cell death 
(for GO functional analysis, see Suppl. Table 2). We 
have previously shown that longevity-associated 
(LAGs) and ARD genes also show functional diversity. 
Besides that, they display a number of distinct features 
including higher connectivity and interconnectivity, 
evolutionary conservation, and essentiality to growth 




























of them putative candidates as antagonistic pleiotropy 
genes, i.e., genes which may have undesirable effects 
later in life, potentially linking aging, longevity and 
ARDs [25, 26]. Therefore, one of the first questions that 
arise in this context is whether CS genes share any 
common features with LAGs and ARD genes.  
 
1.1. Connectivity and interconnectivity: miRNA-
regulated PPI networks 
To what extent are the CS genes/proteins working in a 
cooperative manner? In most cases, proteins do not act 
on their own but rather together with their partners 
through protein-protein interactions (PPIs). Currently, 
the human interactome includes approximately 10,000 
genes with more than 35,000 physical PPIs ([27], 
http://thebiogrid.org). Most of CS genes (231 of the 
262) as well as LAGs and ARD genes can be found in 
the human interactome [24]. As shown in Fig. 1 (insert), 
they have a much higher average connectivity (number 
of first-order protein partners) compared to all 
interactome proteins. This is in accordance with 
observations demonstrating that disease proteins have 
higher average connectivity than other proteins, and that 
highly connected proteins are more likely to be disease-
associated [28]. It was particularly evident for cancer 
genes [22] and for genes common to major human 




























Figure  1.  Fraction  of  CS,  longevity  and  ARD  proteins  forming  a  continuous  PPI  network.  Values  obtained  from
simulations with sets of randomly selected proteins are presented as dots. For all the sets of interest, the fraction of
interconnected  proteins  was  significantly  higher  than  expected  by  chance  (p  <  E‐25).  Insert:  average  connectivity
(number of first‐order protein partners) of the sets analyzed in this study. For more details, see Materials and Methods.
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connected, but they are also highly interconnected. 
Indeed, when compared with randomly generated sets, 
the above genes display a significantly higher 
interconnectivity (the fraction of genes that form a 
continuous network) (Fig. 1).  
 
For example, 59% of the CS genes are connected 
between themselves and eventually form a continuous 
network (Fig. 2), whereas only 4 ± 2% (mean ± SD) 
genes form a network by chance (p < E−25). The 











































higher if other (regulatory) interactions are considered. 
In particular, if we also take into account post-
transcriptional regulation of gene expression by 
microRNAs (miRNAs), almost two thirds (64%) of the 
CS genes become connected, either through PPIs or 
common miRNAs (Fig. 2). Thus, CS genes together 
with their regulatory miRNAs might work in a 
cooperative manner by forming a miRNA-regulated 
PPI network. Such networks are also formed by LAGs 
and ARD genes (currently available in the NetAge 









































































1.2. Essentiality  
Genes with multiple PPIs have a higher probability to 
be essential, just because the deletions of these genes 
may result in the disruption of function of a larger 
number of proteins [28-30]. In line with this 
assumption, the portion of essential genes among the 
CS genes, LAGs and ARD genes is much higher than 
that in the whole genome or interactome (Fig. 3). 
Moreover, there is a significant correlation between 
connectivity and essentiality of different sets examined 
in this study (Fig. 3, insert). It is important to stress that 
many genes essential for development and growth tend 
to have detrimental effects at the later stages of life as 
suggested by the theory of antagonistic pleiotropy [31].   
 
Remarkably, the percent of essential CS genes (42%) is 
considerably higher than that for all   genes (p < E-25) 
and even higher than the percent of essential LAGs (p = 
2.5E-10 and p = 6.2E-06 for entire genome and 
interactome, respectively), genes involved in 
Alzheimer’s disease (p = 1.5E-04 and p = 0.001) and 
aging-associated processes (p < 0.002) (Fig. 3). This 
could at least in part be explained by the fact that the CS 
genes are highly enriched with genes involved in the 
regulation of basic, housekeeping processes such as cell 
cycle, cell growth, programmed cell death, DNA repair, 





























1.3. Evolutionary conservation 
Essential genes are generally more evolutionary 
conserved than non-essential ones [32]. In support of 
this notion are recent findings of Waterhouse et al. [33] 
who demonstrated that the essential genes from model 
organisms are significantly enriched in orthologs across 
the vertebrate, arthropod and fungal lineages. The high 
percentage of essential CS genes led us to explore the 
possibility that CS genes are highly evolutionary 
conserved as a whole. With this in mind, we have 
examined the frequency of orthologs for the human CS 
genes in over 100 species found currently in the 
InParanoid database ([34], http://inparanoid.sbc.su.se). 
We found that CS genes are significantly more 
conserved than are the genes in the whole human 
genome. This is clearly noted across the vertebrate 
species but the difference is insignificant in lower 
organisms. In Fig. 4, this is shown for a selected set of 
well-studied model organisms, from yeast to mouse. 
The same observation was true for the whole 
InParanoid set (data not shown). Notably, the pattern 
of evolutionary conservation of CS genes is almost 
identical to that of cancer-associated genes (see Fig. 
1B in [22]). It would be then tempting to speculate that 
this similarity is a result of the co-evolution between 
these two phenomena. Indirectly supporting this 
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whose fibroblasts do not undergo CS. Instead, they 
display early contact inhibition, an anti-cancer 
mechanism based on cell division arrest before 
reaching a high cell density [36]. Another example is 
chinchilla, a rodent with a low cancer incidence [37] 
that also does not develop CS, but evolved other anti-
cancer adaptations such as continuous slow cell 
proliferation [18].  
 
2. Molecular links between CS genes, LAGs and 
ARD genes 
 
For a more specific analysis, we further addressed the 
following questions: (i) Are there genes common for CS 
and other aging/longevity-related categories? (ii) Could 
genes involved in CS, ARDs and in the control of life 
span interact via direct PPIs or their common partners? 
(iii) Is the set of CS genes enriched in genes associated 
with ARDs and age-related conditions? (iv) Could the 
expression of these genes be under the control of 
common regulatory molecules, more specifically, 
miRNAs? (v) Are there common pathways for CS, 
ARDs and aging-associated processes?  
 
2.1. Common genes  
The analysis revealed that 19% of the CS genes are also 
orthologous to LAGs from model organisms, and 53% 


























1). The highest overlap was observed for cancer (53%); 
lesser values were observed for atherosclerosis (20%), 
Alzheimer's disease (9%) and type 2 diabetes (9%). The 
overlap of CS genes with oxidative stress and chronic 
inflammation associated genes reached 21% and 8%, 
respectively. In all the above cases, the overlap was 
significantly greater than expected by chance (p < E-
25). Notably, among overlapping genes there are many 
which are essential for growth and development (from 
38% to 55%, depending on the gene set). This high 
percentage of essential genes is comparable to that 
found in the Common Gene Signature of longevity and 
major ARD networks [25].  
 
2.2. Protein-protein interactions and common protein 
partners  
Apart from common genes, a great number of CS 
proteins directly interact with LAGs and ARD proteins 
through PPIs (Table 1). As such, the majority of CS 
genes fall either in the category of common genes or in 
that of genes directly connected to LAGs or ARD 
genes. In total, the genes in these two categories exceed 
80% of the entire CS set. In addition, there are many 
common external protein partners, the number of which 
is more than one order of magnitude higher than that of 
common genes. As a result, almost all CS genes are 
linked to longevity and/or ARDs in one of the following 
ways – as common molecules, by forming protein 























































                    AS – Atherosclerosis, AD – Alzheimer’s disease 
 
 
2.3. Common miRNA regulators 
Another important possibility by which CS genes, 
LAGs and ARD genes could be linked is the post-
transcriptional co-regulation of their expression through 
common miRNAs. Among the CS genes, 40 have thus 
far been experimentally validated as being the targets of 
39 miRNAs. Of these miRNAs, almost all have targets 
reported to be involved in cancer and atherosclerosis 
and many have targets associated with other age-related 
conditions and longevity (Table 1). Notably, a large 
number of these miRNAs were indeed found to be 
directly involved in ARDs (Table 2). For example, out 
of the 38 miRNAs regulating the expression of both CS 
and cancer genes, miRNAs belonging to the miR-17, 
miR-19, miR-21, miR-24, miR-155, miR-214, miR-221, 
miR-372, and miR-373 families are oncogenic 
(oncomirs), while miRNAs of the let-7, miR-1, miR-8, 
miR-15, miR-29, miR-34, miR-101, miR-124, miR-125, 
miR-127, miR-145 families have a tumor suppressor 
activity [38, 39, 40, 41]. In fact, as seen in Table 2, all 
the miRNAs common to CS and atherosclerosis, AD or 
type 2 diabetes are also cancer-associated.  
  
2.4. Cancer genes and miRNAs bridge CS with other 
ARDs 
There are many common genes for the major human 
ARDs [22, 23, 25]. What are these genes and how do 
they contribute to the overlaps between CS and ARD 



























genes are highly over-represented among LAGs and in 
all major ARDs and aging-associated conditions (Table 
1). This also follows from the enrichment analysis as 
shown in Fig. 5.  
 
The highest fold-increase (19.3-fold vs. the expected 
value; p < E-25) was found for oxidative stress. This 
was quite expected as oxidative stress is one of the 
major CS inducers [42, 43]. The unexpected 
observation, however, was that the second highest fold-
increase value was found for atherosclerosis (18.7-fold; 
p < E-25), which is almost twice as high as that for 
cancer (10.9-fold; p<E-25) and other ARDs (10-12-
fold; p < E-25). However, further analysis revealed that 
cancer genes are the primary determinants of the links 
between CS and ARDs. Indeed, when the cancer genes 
were removed from the other ARD sets, no significant 
enrichment was found for any of these sets in CS. In 
contrast, after the removal of atherosclerosis, diabetes 
or Alzheimer’s disease genes from the cancer set, the 
enrichment value for cancer genes in CS remained 
almost unchanged. Thus, the cancer genes are central in 
linking CS with other ARDs. Of note, the enrichment 
for CS genes with cancer genes increases when they are 
also represented in another or several other ARDs 
(Table 3). In particular, this can explain the high fold-
increase in the case of atherosclerosis, since almost all 
atherosclerosis genes in CS are also cancer-associated 
(51 of 52). Though the impact of CS on the develop-
   
www.impactaging.com                  1183                                   AGING, December 2011, Vol.3 No.12ment of other ARDs is only beginning to be unveiled, 
accumulating evidence suggests a role of vascular cell 
senescence in atherosclerosis [44] and a clear cellular 
senescence component in type 2 diabetes [45] and 
Alzheimer’s disease [46]. Altogether, our findings 
indicate that (i) cancer genes (together with miRNAs) 
determine the links between CS and other major human 
ARDs, and (ii) CS is particularly enriched in genes 















































3. Common signaling pathways   
 
While analyzing the PPI networks of longevity and 
major human ARDs, we found that about half of the 
common proteins are related to signal transduction [23]. 
Moreover, we showed that the vast majority of these 
proteins are hubs, thus playing a central role in linking 
different ARDs. Therefore, our next question was 






































































































other sets examined in this study. Enrichment analysis 
could serve as a tool for answering this question. We 
found that several pathways are particularly enriched 
across CS, ARDs and aging-associated processes 
(Suppl. Table 3). Surprisingly, among them are many 
growth-promoting pathways such as the MAPK 
signaling, insulin signaling, mTOR signaling, ErbB 
signaling, neurotrophin signalling, etc (Fig. 6). This 
might seem paradoxical, since an irreversible growth 
arrest is the major (though not the only) feature of CS. 
However, recent findings shed light on this apparent 
discrepancy, clearly demonstrating that stimulation of 
cells, which have ceased proliferation, with growth-
promoting mediators induces CS. In other words, 
growth-promoting pathways convert reversible 
quiescence into senescence [12, 47, 48]. Such an 
activation eventually leads to an enhanced secretion of 
cytokines, chemokines, proteases and ROS by senescent 
cells [49], collectively termed as the senescence-
associated secretory phenotype (SASP) [9, 50]. This 
could be especially relevant to aging organisms since 
they display a persistent activation of growth-promoting 

































Figure  5.  Enrichment  of  genes  involved  in  ARDs  and  aging‐
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ment which promotes the development of aging-
associated conditions (chronic inflammation and 
oxidative stress) and ARDs [6, 51, 53]. In addition, the 
formation of the “senescent” microenvironment could 
be greatly attributed to the pathways ensuring cell-cell 
and cell-ECM (extracellular matrix) interactions, such 
as “Focal adhesion” and “Regulation of actin 
cytoskeleton”, which we also found to be significantly 
enriched across CS and ARDs (Fig. 6, Suppl. Table 3). 
In particular, the importance of these pathways in CS is 
highlighted by the fact that the downregulation of 
caveolin-1, a central regulator of focal adhesion kinase 
activity and actin stress fiber formation [54] resulted in 
the re-entry of senescent human fibroblasts into cell 
cycle and restoration of their clonogenic potential [55]. 







































pathways in the common signaling network for the 
major human ARDs and longevity [23]. 
 
Given the over-representation of growth-promoting and 
cell-cell/ECM contact pathways in CS, it was expected to 
see cancer-associated pathways in the enrichment list, 
since cell proliferation and growth promotion are intrinsic 
properties of the cancer cells. Indeed, the most over-
represented category in CS is “Pathways in cancer” 
followed by the pathways for specific forms of cancer, 
including “Bladder cancer”, “Prostate cancer”, “Colo-
rectal cancer”, “Chronic myeloid leukemia”, “Glioma”, 
“Melanoma”, and others and tumor suppressor “p53 
signaling” (Suppl. Table 3). It should however be kept in 
mind that the final outcome (CS or cancer) of activation 
or inhibition of these pathways depends on many 
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involved in cellular response to stress, further linking 
CS with aging and ARDs. For example, the CS-
associated Gadd45 proteins, prominent stress sensors, 
are involved in the determination of the stressed cell 
fate via interactions with p53, MAPK, mTOR and other 
growth-promoting signaling pathways (reviewed by 
Moskalev et al. [56]). An age-related decrease in 
Gadd45 inducibility could promote tumorigenesis, 
immune disorders and insulin resistance [56]. 
Depending on the severity of stress and activated gene 
modules, the CS-associated proteins could either 
mediate DNA repair with subsequent cell survival 
(quiescence or re-entry to cell cycle), or induce CS or 
apoptosis (for details see: [57]). A common event in the 
stressed cells is a down-regulation of insulin/IGF1-Akt-
mTOR axis by up-regulated p53 [58-64]. The resultant 
temporary quiescence period allows the repair of the 
DNA damage and the return to the routine cell cycle. 
However, if the level of stress is too high and/or its 
duration is too long, the cell cycle arrest turns into CS 
or apoptosis [64-67]. The induction of CS is mediated 
by the reactivation of the initially repressed PI3K/Akt-
mTOR pathway [68, 69]. Of note, its activation is also 
considered a hallmark of organismal aging [8, 70, 71]. 
Accordingly, the inhibition of mTOR signaling with 
rapamycin decreased the hypertrophic phenotype of 
senescent cells in vitro [47, 72], extended the lifespan 
and delayed cancer in mice, even when the treatment 
was initiated later in life [73]. Thus, the common 
signaling pathways and the very mechanisms of CS 




Our study shows that CS is tightly interconnected to 
aging, longevity and ARDs, either by sharing common 
genes and regulators or by PPIs and eventually by 
common pathways. The identification of a common 
molecular basis is an important step towards 
understanding the relationships between all these 
conditions. The next natural step would be the 
integration of these data with gene/miRNA expression 
profiles. Such integration could further highlight the key 
players in linking CS and ARDs. However, this is not a 
trivial task as the vast majority of data concerning CS 
derives from in vitro studies on fibroblasts while ARDs 
are well studied in a variety of cells and in vivo systems. 
Broadening the CS investigation by including more cell 
types, 3D in vitro models and in vivo studies will help in 
developing a more holistic view on the CS 
phenomenon.  
 
Our analysis also provides the basis for new predictions 
since the genes common to both cancer and other 
ARD(s) are highly likely candidates to be involved in 
CS and vice versa. In addition, a higher connectivity, 
evolutionary conservation among vertebrates and 
essentiality may increase the probability for CS genes to 
be found as being involved in ARD(s). 
 
Another interesting finding is the similarity between the 
patterns of evolutionary conservation of CS and cancer 
genes, which suggests the co-evolution of these two 
phenomena and calls for a wide comparative study. Of 
special interest would be the investigation of CS in 
species with exceptional longevity and resistance to 
tumors, such as bowhead whales. The comparative 
studies could shed more light on the links between 
cancer and CS, and may help in understanding why 
cancer genes stand at the crossroad of CS and ARDs.  
 
An important point for future investigations is 
examining the role of CS in the formation of an aging 
microenvironment and its impact on the pathogenesis of 
ARDs. In turn, the CS phenotype could be modulated 
by microenvironment. As demonstrated by Choi et al. 
[74], the interaction of senescent cells with ECM from 
young cells is sufficient to restore their replicative 
potential and youthful morphotype. Our present and 
previous [23] in silico analyses together with 
experimental data [55] indicate that a special emphasis 
should be put on focal adhesion and its interactions with 
growth-promoting pathways.  
  
The principal questions remain as to when it is 
worthwhile to induce and when to inhibit CS. What 
strategy is preferable, anti- or pro-CS? These questions 
stem, in particular, from the suggested antagonistic 
nature of CS in cancer [6, 75]. The same dual role of CS 
could also be true for other ARDs but yet has to be 
established. Whatever the case, it seems quite plausible 
that the links between CS and ARDs may vary at 
different stages of disease and life. Induction of CS was 
proposed as a potential anti-cancer therapy [76, 77]. 
Alternatively, the recent study of Baker et al. [10] 
showed that the drug-induced clearance of senescent 
cells from an early age delayed the onset of several age-
related conditions such as sarcopenia, cataracts and loss 
of adipose tissue in progeroid mice, and these beneficial 
effects were also pronounced when the elimination of 
the senescent cells was initiated in the adults. As a 
feasible tool for enhancing the clearance of senescent 
cells, Krizhanovsky et al. [78] suggested 
immunostimulatory therapy. To some extent, in favor of 
the anti-CS strategy are the results of our preliminary 
analysis hinting that the pro-longevity genes are rather 
anti-CS while the pro-CS genes dominate among the 
anti-longevity genes (unpublished data). Given the 
potential benefits of the anti-CS approach, an intriguing 
   
www.impactaging.com                   1187                                  AGING, December 2011, Vol.3 No.12possibility could be based on iPS technology. Using this 
technology, Lapasset et al. [79] demonstrated that 
senescent cells and the cells derived from centenarians 
could be reprogrammed and eventually rejuvenated. As 
a perspective for an in vivo application of this method, 
“a possible scenario may be that after several rounds of 
iP, the microenvironment itself would also assume a 
younger phenotype” [80]. Future studies of the different 
aspects of the links between CS and ARDs will help in 
selecting the most adequate therapeutic strategy.  
 
MATERIALS AND METHODS 
 
A list of genes that have been established as being 
involved in CS was compiled from scientific literature 
and manually curated. The selection of genes was based 
on two lines of evidence: 1) genetic or RNA 
interference (RNAi) interventions (gene knockout, 
partial or full loss-of-function mutations, RNAi-induced 
gene silencing, overexpression) which reportedly cause 
cells to either induce, inhibit or reverse CS, and 2) 
genes shown to be markers of CS. The lists of LAGs 
and the genes involved in ARDs and aging-associated 
processes (oxidative stress and chronic inflammation) 
were obtained from databases and scientific literature as 
described in detail elsewhere [23, 24, 81]. The list of 
differentially expressed miRNAs in CS and of those 
which have been shown to affect CS was gathered and 
manually curated from the scientific literature [82-86]. 
Annotations regarding the involvement of miRNAs in 
different ARDs were taken from the Human MicroRNA 
Disease Database ([87], http://cmbi.bjmu.cn/hmdd). 
Oncogene/Tumor Suppressor classification of cancer-
associated miRNAs was done according to Wang et al. 
[38]. Experimentally validated targets of miRNAs have 
been obtained from the TarBase database ([88], 
http://diana.cslab.ece.ntua.gr/tarbase/) and updated by 
data mining from the scientific literature.  
 
Evolutionary conservation of CS genes was analyzed 
using the InParanoid7 – Eukaryotic Ortholog Groups 
database ([34], http://inparanoid.sbc.su.se). To exclude 
inparalogs, we have used the default threshold score of 
0.05. Essentiality of human genes was evaluated based 
on the data on mouse lethal phenotypes, which were 
retrieved from the Mouse Genome Informatics database 
([89], www.informatics.jax.org). Functional and 
pathway analyses were performed with the tools 
provided by DAVID Bioinformatics Resources 6.7 ([90, 
91], http://david.abcc.ncifcrf.gov) using data from the 
KEGG database ([92], http://www.genome.jp/kegg/ 
pathway.html) and Gene Ontology ([93], 
http://www.geneontology.org). Protein-protein interact-
tion (PPI) data from the BioGRID database ([27], 
http://thebiogrid.org), human interactome release 
3.1.71, was used for the analysis of connectivity and 
interconnectivity. The largest fraction of proteins which 
forms a continuous network was used as a measure of 
interconnectivity. To generate control data, simulations 
with sets of randomly selected proteins from the 
interactome were performed. The size of protein sets 
ranged from 50 to 8000 genes, with a step of 50. In each 
case, one hundred simulations were run and the relation 
between the size of the set and the fraction of genes 
interconnected by chance was quantified. The 
simulations and the creation of the microRNA-regulated 
PPI CS network were done using YABNA (Yet Another 
Biological Networks Analyzer). The YABNA software 
program and the algorithm for the construction of 
miRNA-regulated PPI networks have been previously 
described in detail ([24, 25], http://www.netage-
project.org). The graphical output of the CS miRNA-
regulated PPI network was generated using Cytoscape 
2.8.0 ([94], http://www.cytoscape.org/).  
 
The statistical package for the social sciences (SPSS, 
Inc., Chicago, IL) software was used for the statistical 
evaluation of the results. Significance of the difference 
between mean values was calculated using the Student’s 
t-test. The difference between observed and expected 
values was evaluated using the chi-square test. 
Pearson’s coefficient of correlation was used for pair-
wise correlative analysis. Differences were considered 
significant at p-value less than 0.05. Statistical analysis 
of the enrichment of GO categories and KEGG 
pathways was carried out using DAVID Bioinformatics 
Resources 6.7 ([90, 91], http://david.abcc.ncifcrf.gov), 
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